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BACKGROUND: Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard-of-
care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in con-
ducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received
treatment with drug regimens that were first tested in patient-derived xenografts using a proprietary method (“TumorGrafts”).
METHODS: Tumors resected from 29 patients with sarcoma were implanted into immunodeficient mice to identify drug targets and
drugs for clinical use. The results of drug sensitivity testing in the TumorGrafts were used to personalize cancer treatment. RESULTS:
Of 29 implanted tumors, 22 (76%) successfully engrafted, permitting the identification of treatment regimens for these patients.
Although 6 patients died before the completion of TumorGraft testing, a correlation between TumorGraft results and clinical outcome
was observed in 13 of 16 (81%) of the remaining individuals. No patients progressed during the TumorGraft-predicted therapy.
CONCLUSIONS: The current data support the use of the personalized TumorGraft model as an investigational platform for therapeu-
tic decision-making that can guide treatment for rare tumors such as sarcomas. A randomized phase 3 trial versus physician’s choice
is warranted. Cancer 2014;120:2006–15. VC 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American
Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs
License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial
and no modifications or adaptations are made.
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INTRODUCTION
Sarcomas represent a heterogeneous and diverse group of tumors; and, because of the rarity of each subtype, there is a lack of
randomized data from which we can guide systemic, nonsurgical treatments.1 Gene expression profiling has led to significant
advances in diagnosis and prognosis, and additional genetic studies have led to a better understanding of underlying chromo-
somal translocations in sarcoma.2-6 However, with the exception of gastrointestinal stromal tumors and Kaposi sarcoma,
therapeutic options are limited, because drugs that directly target the fusion oncoproteins produced are not available. Molec-
ular pathways activated by these fusion oncogenes may still be targeted, and inhibitory agents have been developed.7-9
Because sarcomas are usually somatic genetic diseases and tumorigenesis depends on permissive microenvirno-
ments,10 others have developed reliable mouse models that faithfully recapitulate the histopathologic, immunohisto-
chemical, and transcriptional profile of human sarcomas, to the extent that 1 notable study appeared to identify the
cell of origin for synovial sarcomas.11 Such models are valuable resources for studying tumor biology and are a strik-
ing example of how understanding normal tissue in the context of cancer growth will be central to developing appro-
priate therapies.12 These models are also more likely to be reliable indicators of in vivo tumor behavior and metastatic
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progression compared with cell line data, which only
partially mimic the genetic features of cancer.13,14
Indeed, differences between cell lines and cancers can
often reflect intratumor heterogeneity and adaptation
through Darwinian selection.15 Nevertheless, although
these models are more reliable indicators of in vivo
growth, the rarity of sarcoma as well as patient diversity
makes identifying and testing targeted therapies difficult
and underscores the need to find real-time, personalized
solutions for patients with sarcoma.
The use of tumor tissue engrafted into immune-
deficient mice, termed “TumorGrafts” (Champions On-
cology, Inc., Baltimore, Md), should overcome many of
the aforementioned issues and allow a personalized
approach to cancer therapy. This process preserves the
characteristics of the live tumor, creating a replica that
appears identical to the tumor in the patient’s body, as
characterized by genetic, genomic, and biochemical meth-
ods.16,17 The entire process, depicted in Figure 1A,
typically takes 3 to 6 months, and approximately 75% of
implanted tumors grow successfully in mice. Indeed,
unique banks of serially transplantable, orthotopic,
patient-derived TumorGrafts that retain that characteris-
tics of the original tumor have been established for a series
of breast cancers16 and colorectal cancers,17 along with
case reports in pancreatic, adenoid cystic, and other tumor
types,18-20 all of which were used to customize therapy.
Herein, we describe our experience with TumorGrafts in
29 individuals who had advanced sarcoma, a disease for
which few treatment options are available.
MATERIALS AND METHODS
TumorGraft Generation
Patients in the United States and Europe who were diag-
nosed with advanced sarcoma had the opportunity to
have their tumors engrafted for the generation of a
Figure 1. This is a schematic of the TumorGraft engraftment and testing process. A piece of the patient’s tumor is collected at
the time of surgery and implanted into immunocompromised mice for the purpose of propagation. While the patient recovers
from surgery and receives treatment with first-line therapies, the TumorGraft is expanded across more mice (generations P0-P3).
These engrafted mice eventually are enrolled in a drug-screening test to determine optimal treatments (RX). Test results are pre-
sented to the patient’s treating oncologist to help guide later stages of therapy.
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personalized TumorGraft. Patients who chose to partici-
pate were charged a fee to enroll and signed an informed
consent document. The informed consent document fol-
lowed federal regulatory requirements and covered the use
of the patient’s tumor for personalizing therapy, reporting
of patient medical history, and use of tumor material for
research purposes. A fresh specimen of the patient’s tumor
was removed by a surgeon at the time of resection or bi-
opsy and sent to a dedicated laboratory. Fragments of the
tumor measuring approximately 4 mm3, containing both
malignant cells and supportive stromal components, were
implanted subcutaneously into the flanks of 6-week-old
immunodeficient mice, as previously described (female
nu=nu athymic mice; Harlan Laboratories, Indianapolis,
Ind.).16-20 The mice (P1 generation) were maintained
under pathogen-free conditions and a 12-hour light=dark
cycle. When P1 tumors reached an approximate size of
1500 mm3, they were harvested, fragmented, and reim-
planted into additional mice (P2 generation) while main-
tained as a live bank according to approved Institutional
Animal Care and Use Committee protocols. When
enough P2 TumorGrafts reached a volume greater than
200 mm3, the animals were divided into groups of 3 to 5,
and dosing of drugs or drug combinations was imple-
mented according to the individual physician’s choice and
in consultation with the specific patient. Starting volumes
varied between different TumorGraft models because of
the individual doubling time.
Agent Efficacy
All test agents were formulated according to the manufac-
turer’s specifications. Beginning on day-0, tumor dimensions
were measured twice weekly by digital caliper; and data,
including individual and mean estimated tumor volumes,
were recorded for each group. Tumor volume (TV) was cal-
culated using the formula:TV5width23 length3 p=2.
Tumor Growth Inhibition and Response
Evaluation Criteria in Solid Tumors
At study completion, percentage tumor growth inhibi-
tion (%TGI) values were calculated for each treatment
group (T) versus control (C) using initial (i) and final (f)
tumor measurements according to the formula:
%TGI5 (12 [Tf2Ti]=[Cf2Ci])3 100. Individual
mice that had a tumor volume >120% of the day-0
measurement were considered to have progressive dis-
ease (PD). Individual mice with neither sufficient
shrinkage nor sufficient tumor volume increases were
considered to have stable disease (SD). Individual mice
that had a tumor volume 70% of the day-0 measure-
ment for 2 consecutive measurements over a 7-day pe-
riod were considered to have a partial response (PR). If
the PR persisted until study completion, then the per-
centage tumor regression (%TR) was determined using
the formula: %TR5 (12 [Tf=Ti])3 100; and a mean
value was calculated for the entire treatment group.
Individual mice that lacked palpable tumors for 2 con-
secutive measurements over a 7-day period were consid-
ered to have a complete response (CR). All data
collected in this study were managed electronically and
stored on a redundant server system. %TGI and %TR
values were ranked according to their efficacy and were
provided to the treating physician, who selected an
appropriate therapy in consultation with the patient. All
investigations were performed after approval by local
committees.
RESULTS
In total, 29 patients with heavily pretreated, advanced sar-
comas entered the study (Table 1, Fig. 1B). Sarcomas
from 7 patients failed to successfully engraft in the mice,
perhaps indicative of more slow-growing tumors, as sug-
gested previously,16 or perhaps an effect of prior chemo-
therapy. Of the 22 patients who had successful
engraftment and growth in mice, 6 died before data
became available; therefore, therapeutic testing for them
was abandoned. Of the 16 remaining patients, 13 (81%)
demonstrated a correlation between results from their
TumorGraft and their clinical outcome, including 3
patients whose TumorGrafts were tested more than once.
Among these 13 patients, 6 experienced a direct clinical
benefit from TumorGraft-directed therapy, and 7 had a
retrospective analysis performed on their behalf that
yielded a positive correlation between their postresection
regimens and the response observed in their Tumor-
Grafts. The individual patients enrolled on the study are
further characterized and summarized in Table 1 and are
described below.
POS-1119
This man aged 55 years presented with a diagnosis of
advanced, aggressive, high-grade, dedifferentiated liposar-
coma of the mesentery (Fig. 2A). Six months after his first
surgical resection, he demonstrated widespread recur-
rence, at which time a TumorGraft was established. Gene
sequencing (exome sequencing using the Illumina plat-
form [Illumina Inc., San Diego, Calif] to compare 50 mil-
lion bases of tumor and normal DNA18,21) revealed a
mutation in Janus kinase 2 (JAK2) as well as cyclin-
dependent kinase 4 (CDK4) and mouse double minute 2
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homolog (MDM2) copy number alterations, both of
which are commonly detected in liposarcomas. High
expression of CDK4 and MDM2 was further corrobo-
rated using immunohistochemical analysis (data not
shown). The patient commenced daily treatment with a
CDK4 inhibitor (350 mg P1446A-05), which, at first,
inhibited the rapid growth of the tumors, as detected by
computed tomography (CT) scans. This treatment was
then supplemented with a JAK2 inhibitor (ruxolitinib), in
agreement with the correlative, retrospective TumorGraft
data (Fig. 2B). This produced limited clinical benefit, as
indicated by a decrease in size of 1 of the tumors followed
by the appearance of 2 new lesions at 3 months and 4
months of treatment, respectively. Prospective Tumor-
Graft model drug-sensitivity testing was completed, and
the results demonstrated tumor growth inhibition of
117% after treatment with ifosfamide, and all animals
demonstrated SD. Moreover, treatment with a combina-
tion of gemcitabine and docetaxel resulted in tumor
growth inhibition of 93% in the models. At the time of
disease progression, the patient commenced 5 cycles of
TumorGraft-directed therapy with ifosfamide, which
resulted in an objective response (Fig. 2C). This was fol-
lowed by 5 months of daily TumorGraft-directed regora-
fenib, which had demonstrated a %TGI value of 144% in
the mice, leading to a PR in all animals. Clinical use of
regorafenib resulted in further tumor regression of all
nodules, and treatment is still ongoing.
POS-1130
This woman aged 52 years had a high-grade, pleomor-
phic, spindle and epithelioid tumor (Fig. 3A). After the
tumor was resected, a TumorGraft model was established.
The results demonstrated tumor regression after treat-
ment either with a combination of docetaxel and gemcita-
bine or with doxorubicin (as a single agent), which
TABLE 1. TumorGraft Results and Clinical Outcome for Sarcoma Patientsa
Patient No. Identifier Sarcoma histology TumorGraft and Outcome Status
1 601 Leiomyosarcoma Direct clinical benefit demonstrated
2 1119b Liposarcoma Direct clinical benefit demonstrated
3 12113 Spindle cell sarcoma Direct clinical benefit demonstrated
4 1241b Myxoma Direct clinical benefit demonstrated
5 1207b Ewing sarcoma Direct clinical benefit demonstrated
6 602 Chondrosarcoma Direct clinical benefit demonstrated
7 1130b Spindle cell sarcoma Clinical benefit; retrospective clinical
correlation demonstrated
8 1255b Liposarcoma Mice data available, but not yet used clinically;
retrospective clinical correlation demonstrated
9 12111 Multifocal sarcoma Mice data available, but not yet used clinically;
retrospective clinical correlation demonstrated
10 13034 Phyllodes sarcoma Mice data available, but not yet used clinically;
retrospective clinical correlation demonstrated
11 1009b Rhabdomyosarcoma Died before using the data; retrospective clinical
correlation demonstrated
12 1174 Rhabdomyosarcoma Died before using the data
13 1152b Synovial sarcoma Died before using the data; retrospective clinical
correlation demonstrated
14 13030 Ewing sarcoma Mice data is available but not yet used clinically
15 13022 Sarcoma, unspecified Ongoing study
16 1104 Leiomyosarcoma Patient has remained disease free postoperatively
17 138 Rhabdomyosarcoma Died before using the data
18 1278 Liposarcoma Died before using the data
19 13014 Liposarcoma Died before using the data
20 1132 Myxoma Died before using the data
21 1164 Ewing sarcoma Died before using the data
22 12106 Small round cell sarcoma Died before using the data
23 1115 Rhabdomyosarcoma Failed to grow
24 1012 Synovial sarcoma Failed to grow
25 1276 Liposarcoma Failed to grow
26 1156 Spindle cell sarcoma Failed to grow
27 1282 Spindle cell sarcoma Failed to grow
28 1259 Sarcoma, unspecified Failed to grow
29 1283 Sarcoma, unspecified Failed to grow
a This is a list of patients with sarcoma who were engrafted for TumorGraft studies. The patients are listed according to whether or not clinical benefit was
demonstrated. TumorGraft testing results are provided along with clinical information.
bData on these patients are presented in the text (see Results) and are illustrated in the figures.
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produced %TGI values of 135% and 111%, respectively;
and the mice demonstrated a spectrum of responses,
including SD, PR, and CR. Treatment with ifosfamide,
sunitinib, combined carboplatin and paclitaxel, or vorino-
stat produced modest to minimal tumor growth inhibi-
tion, with %TGI values of 80%, 66%, 59%, and 20%,
respectively. All TumorGrafts in these groups demon-
strated PD. The patient commenced treatment with gem-
citabine and docetaxel and demonstrated a very good PR
for 10 months. Upon disease progression around the
lower pelvic scar, she commenced treatment with doxoru-
bicin, again according to the TumorGraft-directed ther-
apy (Fig. 3B). Today, after 8 months, the patient is still
demonstrating a response, although the treating physician
(1 of the authors of the current report [J.S.]) has switched
the patient to liposomal doxorubicin to decrease the
potential for cardiac toxicity.
POS-1207
This boy, now aged 9 years, was diagnosed at age 6 years
with Ewing sarcoma of the left scapula with bilateral pul-
monary metastases (Fig. 4A). The tumor was positive for
the Ewing sarcoma=Fli-1 proto-oncogene, ETS transcrip-
tion factor (EWS-FLI1) fusion gene rearrangement. Ini-
tial therapy consisted of 7 cycles of intensively dosed
vincristine with doxorubicin and cyclophosphamide
(cycles 1-3 and 7) and ifosfamide plus etoposide given
over 6 months; scapulectomy after cycle 3 revealed pre-
dominantly viable residual tumor (grade I necrosis). Con-
solidative whole-lung irradiation (1500 centigrays in 10
fractions) was administered 11 months postdiagnosis after
the completion of 6 cycles of adjuvant “maintenance
therapy” with irinotecan plus temozolomide. Recurrent,
subcentimeter, left-sided pulmonary metastases developed
8 months later. Three fully viable metastatic nodules
Figure 2. Clinical and TumorGraft data are illustrated for patient POS-1119. (A) Histology of the TumorGraft reveals a dedifferenti-
ated liposarcoma, similar to results from the patient’s pathology reports. (B-D) TumorGraft sensitivity testing was performed to
determine which drugs would be effective against the patient’s tumor. Ruxolitinib, regorafenib, and ifosfamide significantly
blocked tumor growth during TumorGraft testing. Asterisks denote significance (a single asterisk indicates P .05; double aster-
isks, P .01; triple asterisks, P .001). (E) Radiology reports for patient POS-1119 demonstrate a partial response after treatment
with ifosfamide.
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(measuring 2 mm, 6 mm, and 11 mm) were resected after
7 cycles (6 months) of cyclophosphamide plus topotecan
relapse therapy, at which time a sample was submitted for
drug-sensitivity testing to evaluate the activity of 5 differ-
ent regimens with 1 investigational drug arm. The results
demonstrated a %TR value of 64% after treatment with
the combination of gemcitabine, docetaxel, and bevacizu-
mab with a %TGI value of 122%. Treatment with pazo-
panib as a single agent yielded a moderate %TGI value of
47%, whereas treatment with gemcitabine and mithramy-
cin A as single agents produced no benefit compared with
control. Postoperatively, rapid disease recurrence=prog-
ression occurred during continued treatment with 3 addi-
tional cycles of cyclophosphamide plus topotecan.
Subsequently, rapid disease progression occurred over 1
month during treatment on a phase 1 trial of an investiga-
tional immunostimulating virus. Treatment with a
combination of an insulin-like growth factor 1 (IGF1)-
receptor antibody and a mechanistic target of rapamycin
(serine=threonine kinase) (mTOR) inhibitor during a
phase 2 trial produced SD at 6 weeks followed by PD at
3 months; murine testing of this same combination
(unnamed because of company restrictions) resulted in
growth inhibition, and all tumor-bearing mice demon-
strated SD (data not presented; clinical trial ongoing). On
the basis of the results from TumorGraft experiments,
treatment with the combination of docetaxel, gemcita-
bine, and bevacizumab was started (Fig. 4B). After 2
cycles of treatment, the patient had a CT scan that
revealed PR (Fig. 4C); ongoing radiographic improve-
ment was observed after 5 treatment cycles, and the
patient remains on this therapy 6 months after the start
of treatment.
POS-1241
This man aged 48 years was diagnosed 5 years ago with
metastatic myxoma to the lung and the neck and has a
history of testicular and renal cancer before that. The
patient went through several lines of therapy, most
recently including treatments with gemcitabine, doxoru-
bicin, sorafenib, and others. The patient’s tumor was
resected, and a TumorGraft model was generated and
tested against several lines of therapy, as illustrated in Fig-
ure 5. The patient commenced TumorGraft-guided
Figure 3. Clinical and TumorGraft data are illustrated for patient POS-1130. (A) Histology of the TumorGraft reveals a high-grade,
pleomorphic, spindle and epithelioid sarcoma. (B,C) TumorGraft sensitivity testing was performed to determine which drugs
would be effective against the patient’s tumor. Everolimus, doxorubicin, eribulin, and a combination of docetaxel and gemcitabine
proved effective using TumorGraft technology. Asterisks denote significance (a single asterisk indicates P .05; double asterisks,
P.01; triple asterisks, P .001).
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treatment with irinotecan and temozolomide, and a CT
scan performed at the completion of 2 cycles (6 weeks)
demonstrated evidence of a favorable response with
reduction in pleural effusions and a decrease in the size of
multiple lung metastases.
POS-1009
This man aged 49 years with a grade 3 pleomorphic rhab-
domyosarcoma presented with >40 metastases in his
lungs. After tumor resection, a TumorGraft model was
generated. A retrospective analysis demonstrated growth
inhibition after treatment with sunitinib as a single agent
and with a combination of docetaxel, gemcitabine, and
bevacizumab, which produced %TGI values of 98% and
80%, respectively (Fig. 6A). The patient commenced
treatment with the combination of docetaxel, gemcita-
bine, and bevacizumab and had a PR for approximately 6
months, although SD was predicted (data not shown).
POS-1152
This man aged 57 years had a heavily pretreated, meta-
static sarcoma of the perineum with an synaptotagmin
(SYT) translocation consistent with synovial sarcoma.
The patient experienced several remissions and recur-
rences for more than 6 years and most recently progressed
Figure 4. Clinical and TumorGraft data are illustrated for patient POS-1207. (A) Histology of the TumorGraft confirms Ewing sar-
coma. (B) TumorGraft sensitivity testing was performed to determine which drugs would be effective against the patient’s tumor.
A combination of docetaxel, gemcitabine, and bevacizumab proved effective using TumorGraft technology. Asterisks denote sig-
nificance (a single asterisk indicates P .05; double asterisks, P .01; triple asterisks, P .001). (C) Radiology reports for patient
POS-1119 demonstrate a partial response after treatment with ifosfamide.
Figure 5. TumorGraft sensitivity testing is illustrated for
Patient 1241 (POS-1241), who was diagnosed with metastatic
myxoma. TumorGraft testing demonstrates significant tumor
growth inhibition after treatment with a combination of either
ifosfamide and etoposide or irinotecan and temozolomide.
Asterisks denote significance (triple asterisks indicate
P.001).
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in the lung. A progressing lung lesion was resected as in
patient POS-1009 and allowed for the generation of a
TumorGraft model and chemosensitivity testing of 7
drug combinations. The drug-sensitivity test demon-
strated growth inhibition after treatment with ifosfamide
and with trabectedin, which produced %TGI values of
91% and 99%, respectively, and all 3 study animals dem-
onstrated SD. Treatment with gemcitabine, pazopanib,
etoposide or with a combination of etoposide and vorino-
stat demonstrated moderate effects on tumor growth,
with %TGI values of 43%, 56%, 23% and 23%, respec-
tively (Fig. 6B,C). Genome analysis of the patient’s tumor
revealed a mutation leading to abnormal splicing of
patched (PTCH1). PTCH1 inhibits the smoothened re-
ceptor and hedgehog signaling. However, vismodegib, an
antagonist of the smoothened receptor that acts down-
stream of PTCH1, exhibited no efficacy in this Tumor-
Graft model. The patient commenced ifosfamide
treatment in parallel to the drug-sensitivity testing in the
mice and, in agreement with TumorGraft data, experi-
enced 6 months of SD.
POS-1255
This man aged 74 years with metastatic, dedifferentiated
liposarcoma was diagnosed 8 years ago and received sev-
eral lines of therapy, including trabectedin, ifosfamide,
and sunitinib, all of which resulted in PD. The patient
then received treatment with eribulin for approximately 3
years and attained a clear PR, but he progressed and devel-
oped an eribulin-resistant tumor. The patient com-
menced pazopanib treatment for 5 months, which
resulted in SD. His tumor was resected, and a Tumor-
Graft model was generated and tested against the afore-
mentioned drugs to retrospectively compare the tumor’s
sensitivity. Treatment with eribulin resulted in a moderate
growth inhibition with %TGI value of 63%. Treatment
with sunitinib resulted in a minor %TGI value of 41%
Figure 6. Retrospective TumorGraft testing is illustrated. (A) Retrospective TumorGraft testing for patient POS-1009 reveals sig-
nificant growth reduction with a combination of gemcitabine and docetaxel. (B,C) Retrospective TumorGraft testing for patient
POS-1152 indicates strong antitumor effects with either trabectidin or ifosfamide. (D) Retrospective TumorGraft testing for
patient POS-1255 demonstrates that, although eribulin and sunitinib slow tumor growth relative to controls, the patient’s tumor
still grows, albeit more slowly. Asterisks denote significance (a single asterisk indicates P .05; double asterisks, P .01; triple
asterisks, P.001).
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(Fig. 6D). Treatment with trabectedin, ifosfamide, and
pazopanib is ongoing.
DISCUSSION
The development of personalized mouse models for
patients with cancer is useful for drug screening and bio-
marker development, and it also may have predictive
capacity in a group of heterogeneous patients with
difficult-to-treat, advanced cancers. Results of studies by
us and others support the use of TumorGrafts as a reliable
and consistent method to provide direction for optimiz-
ing personalized cancer treatment and may deliver an
innovative opportunity for patients and their oncologist
when faced with a challenging therapeutic spectrum. In
some of these individuals, TumorGraft responses were
used on more than 1 occasion to accurately predict
responses to several lines of therapy without requiring
fresh tissue grafting.
Although these clinical cases were not randomized
versus physician’s best choice, we suggest that the response
rates, durability of responses, and precision of the drug
combinations were above standard expectations. Such an
approach is not without its difficulties. Limitations
include the need for a sufficient amount of fresh tissue,
which can be difficult considering that many of these
patients are not otherwise scheduled for surgery. In addi-
tion, although the development and propagation of a
TumorGraft model can take as little as 6 weeks, it is more
often up to 6 months before study results can be made
available. This timeline directly correlates with tumor
aggressiveness, invasiveness, and the quality and quantity
of malignant tissue received. Furthermore, it is conceiva-
ble that this prolonged timeline also allows additional
DNA alterations to occur within the patient tumor, and
thus a careful consideration of the patient medical history
with a particular focus on previous treatments should be
incorporated into the drug-sensitivity study design.
Finally, there is a 20% failure rate in TumorGraft estab-
lishment, although anecdotal evidence suggests that this
may indicate that the patient’s cancer is perhaps less
“aggressive.” Indeed, the ability of a tumor to grow in
mice may indicate a more aggressive phenotype; and, in 1
previous study, positive engraftment was correlated with
shorter survival.16
One of the primary advantages of the TumorGraft is
that it allows discrimination between the different
standard-of-care therapies that may be available, as well as
other potential treatments not normally indicated for that
tumor. Our increased understanding of tumor heteroge-
neity, even within a single subtype, means that knowing
how patients with the same tumor previously responded
to a particular drug is no guarantee that the current
patient will respond similarly. The TumorGraft over-
comes this problem by helping guide oncologists to those
treatments that are most likely to provide a positive clini-
cal outcome. In addition, TumorGrafts also provide an
opportunity to test nonmarketed drugs in development.
This approach not only provides the patient and their
oncologist with an insight into the potential response in a
clinical trial setting, but it also allows a better understand-
ing of the tumorigenesis mechanism of their specific tu-
mor. With TumorGrafts, the performance status of the
patient can be considered when deciding which drugs to
test, keeping in mind the known toxicity profiles of these
therapies.
Even in our modern era of oncology with
biomarker-enriched populations, response rates are fre-
quently far from satisfying. For example, among the sub-
population of metastatic colorectal cancers that carry the
wild-type Kirsten rat sarcoma viral oncogene homolog
(KRAS) allele, objective responses to antiepidermal
growth factor receptor therapeutics is still confined to
13% to 17% of patients.22-24 Although the identification
of v-raf murine sarcoma viral oncogene homolog B
(BRAF), phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit a (PIK3CA), neuroblastoma v-ras onco-
gene homolog (NRAS), and rare KRAS mutations may
increase this percentage, there is a lack of standard thera-
peutic options, and the issue of tumor and=or patient het-
erogeneity in clinical trials remains important. Moreover,
only a small fraction of tumors harbor these specific alter-
ations, meaning that the majority of patients with
advanced cancer will receive no benefit from these thera-
pies. The TumorGraft approach may overcome these
issues and represents a truly personalized approach.
There have been other attempts to develop personal-
ized approaches to cancer therapy. For example, in vitro
sensitivity assays exist in which a patient’s tumor is disag-
gregated and plated into tissue culture flasks before drug
treatment to assess which drugs induce tumor cell death.25
Although these have demonstrated some value, the narrow
window over which these assays are performed means that
only those drugs that appear to kill effectively can be iden-
tified, perhaps excluding therapies that are effective at
blocking tumor growth without inducing cell death. For
example, in Figure 5, at first, it appears that vorinostat is
effective, and in vitro testing also may have suggested that
this was the case. However, the tumor recovers, and
growth accelerates rapidly in the mouse model, indicating
that, in fact, vorinostat is unlikely to be of clinical benefit
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to the patient. Moreover, in vitro sensitivity tests still lack
the 3-dimensional interplay between tumor, stroma, and
other cells fluxing into the environment, all of which can
have a marked impact on drug responses.26
The TumorGraft models used here include the tu-
mor microenvironment present in the human host and
maintain the features of the transplanted tumor, including
gene expression profiles, copy number variants, and, most
important, treatment response.16 Serially passaged tumors
retain the morphologic and genomic features of their orig-
inal counterparts.17 TumorGrafts derived from surgical
specimens conserve the interindividual diversity and the
genetic heterogeneity typical of the tumors of origin.17 In
those patients reported herein who had TumorGraft
models that grew, and for those who had a drug-
sensitivity evaluation in the mice, the clinical response
rates appeared to be impressive. For sarcoma patients with
few standard options, this approach is promising, and the
limitations of speed and cost should be resolved with
time.
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